Published in J Cell Mol Med on May 01, 2009
TGFbeta in Cancer. Cell (2008) 17.44
TGF-beta signaling in tumor suppression and cancer progression. Nat Genet (2001) 11.64
Transcriptional control by the TGF-beta/Smad signaling system. EMBO J (2000) 8.49
Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet (2002) 7.67
Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology (2004) 6.98
The two faces of transforming growth factor beta in carcinogenesis. Proc Natl Acad Sci U S A (2003) 4.41
Signaling of transforming growth factor-beta family members through Smad proteins. Eur J Biochem (2000) 2.39
Transforming growth factor-beta gene expression signature in mouse hepatocytes predicts clinical outcome in human cancer. Hepatology (2008) 2.04
Growth inhibition by transforming growth factor beta (TGF-beta) type I is restored in TGF-beta-resistant hepatoma cells after expression of TGF-beta receptor type II cDNA. Proc Natl Acad Sci U S A (1993) 1.64
Functional and genomic implications of global gene expression profiles in cell lines from human hepatocellular cancer. Hepatology (2002) 1.51
Novel recurrent genetic imbalances in human hepatocellular carcinoma cell lines identified by comparative genomic hybridization. Hepatology (1999) 1.50
Refined localization of the erbB-3 proto-oncogene by direct visualization of FISH signals on LUT-inverted and contrast-enhanced digital images of DAPI-banded chromosomes. Cancer Genet Cytogenet (1995) 1.34
Human hepatocellular carcinoma (HCC) cells require both alpha3beta1 integrin and matrix metalloproteinases activity for migration and invasion. Lab Invest (2001) 1.33
Transforming growth factor beta: tumor suppressor or promoter? Are host immune cells the answer? Cancer Res (2008) 1.31
Proinflammatory cytokines induce liver and activation-regulated chemokine/macrophage inflammatory protein-3alpha/CCL20 in mucosal epithelial cells through NF-kappaB [correction of NK-kappaB]. Int Immunol (2001) 1.17
Deleted in liver cancer 3 (DLC-3), a novel Rho GTPase-activating protein, is downregulated in cancer and inhibits tumor cell growth. Oncogene (2007) 1.12
Somnogenic, pyrogenic, and anorectic activities of tumor necrosis factor-alpha and TNF-alpha fragments. Am J Physiol (1992) 1.10
The type II transforming growth factor-beta receptor as a tumor-suppressor gene. Curr Opin Oncol (1996) 1.07
A comprehensive karyotypic study on human hepatocellular carcinoma by spectral karyotyping. Hepatology (2000) 0.99
Tumor necrosis factor-alpha inhibits surfactant protein C gene transcription. J Biol Chem (1995) 0.95
Novel genomic imbalances and chromosome translocations involving c-myc gene in Burkitt's lymphoma. Leukemia (2001) 0.91
SMAD5 gene expression, rearrangements, copy number, and amplification at fragile site FRA5C in human hepatocellular carcinoma. Neoplasia (2003) 0.86
Differential modulation of astrocyte cytokine gene expression by TGF-beta. J Immunol (1994) 0.86
Secretion of complement components of the alternative pathway (C3 and factor B) by the human alveolar type II epithelial cell line A549. Int J Mol Med (2000) 0.83
mRNA expression of complement components and regulators in rat arterial smooth muscle cells. Microbiol Immunol (1999) 0.81
Divergent transforming growth factor-beta effects on IL-6 regulation of acute phase plasma proteins in rat hepatoma cells. J Immunol (1993) 0.81
Linkage and association of CYP17 gene in hereditary and sporadic prostate cancer. Int J Cancer (2001) 0.80
Prevalence of chronic kidney disease in China: a cross-sectional survey. Lancet (2012) 10.53
Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology (2004) 6.98
A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med (2006) 6.31
Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res (2009) 5.68
Hippo signaling is a potent in vivo growth and tumor suppressor pathway in the mammalian liver. Proc Natl Acad Sci U S A (2010) 4.95
Senescing human cells and ageing mice accumulate DNA lesions with unrepairable double-strand breaks. Nat Cell Biol (2004) 4.87
Hepatocyte growth factor/c-met signaling pathway is required for efficient liver regeneration and repair. Proc Natl Acad Sci U S A (2004) 4.17
Application of comparative functional genomics to identify best-fit mouse models to study human cancer. Nat Genet (2004) 3.97
Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. Gastroenterology (2006) 3.95
Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype. J Clin Invest (2006) 3.95
Regulation of tumor angiogenesis by EZH2. Cancer Cell (2010) 3.10
Enrichment of a population of mammary gland cells that form mammospheres and have in vivo repopulating activity. Cancer Res (2007) 3.04
Telomerase contributes to tumorigenesis by a telomere length-independent mechanism. Proc Natl Acad Sci U S A (2002) 2.82
Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. Gastroenterology (2011) 2.63
A unique metastasis gene signature enables prediction of tumor relapse in early-stage hepatocellular carcinoma patients. Cancer Res (2010) 2.59
Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma. J Clin Invest (2007) 2.53
Sixty-five gene-based risk score classifier predicts overall survival in hepatocellular carcinoma. Hepatology (2012) 2.40
Dominant role of hepatitis B virus and cofactor role of aflatoxin in hepatocarcinogenesis in Qidong, China. Hepatology (2002) 2.38
Intrinsic subtypes of gastric cancer, based on gene expression pattern, predict survival and respond differently to chemotherapy. Gastroenterology (2011) 2.36
High-penetrance mouse model of acute promyelocytic leukemia with very low levels of PML-RARalpha expression. Blood (2003) 2.26
GTF2IRD1 in craniofacial development of humans and mice. Science (2005) 2.15
Deletion of p120-catenin results in a tumor microenvironment with inflammation and cancer that establishes it as a tumor suppressor gene. Cancer Cell (2011) 2.10
DLC-1:a Rho GTPase-activating protein and tumour suppressor. J Cell Mol Med (2007) 2.09
Thioacetamide-induced hepatic fibrosis in transforming growth factor beta-1 transgenic mice. Eur J Gastroenterol Hepatol (2004) 2.06
LIN28B promotes colon cancer progression and metastasis. Cancer Res (2011) 2.05
Inactivation of Ras GTPase-activating proteins promotes unrestrained activity of wild-type Ras in human liver cancer. J Hepatol (2010) 2.05
Transforming growth factor-beta gene expression signature in mouse hepatocytes predicts clinical outcome in human cancer. Hepatology (2008) 2.04
Progenitor-derived hepatocellular carcinoma model in the rat. Hepatology (2010) 2.03
Functional genomics of hepatocellular carcinoma. Hepatology (2006) 2.02
Downregulation of KLF6 is an early event in hepatocarcinogenesis, and stimulates proliferation while reducing differentiation. J Hepatol (2006) 1.98
The RhoGAP protein DLC-1 functions as a metastasis suppressor in breast cancer cells. Cancer Res (2005) 1.94
DLC-1 operates as a tumor suppressor gene in human non-small cell lung carcinomas. Oncogene (2004) 1.90
Label-retaining liver cancer cells are relatively resistant to sorafenib. Gut (2013) 1.89
Oncogenic inhibition by a deleted in liver cancer gene requires cooperation between tensin binding and Rho-specific GTPase-activating protein activities. Proc Natl Acad Sci U S A (2007) 1.87
Sulfatase 2 up-regulates glypican 3, promotes fibroblast growth factor signaling, and decreases survival in hepatocellular carcinoma. Hepatology (2008) 1.87
Delayed kinetics of DNA double-strand break processing in normal and pathological aging. Aging Cell (2007) 1.84
Gene expression signature-based prognostic risk score in gastric cancer. Clin Cancer Res (2011) 1.83
Identification of a cholangiocarcinoma-like gene expression trait in hepatocellular carcinoma. Cancer Res (2010) 1.82
The adaptive imbalance in base excision-repair enzymes generates microsatellite instability in chronic inflammation. J Clin Invest (2003) 1.82
Dual inhibition of tumor energy pathway by 2-deoxyglucose and metformin is effective against a broad spectrum of preclinical cancer models. Mol Cancer Ther (2011) 1.81
Astrocytes upregulate survival genes in tumor cells and induce protection from chemotherapy. Neoplasia (2011) 1.78
Modeling pathogenesis of primary liver cancer in lineage-specific mouse cell types. Gastroenterology (2013) 1.76
DLC-1 gene inhibits human breast cancer cell growth and in vivo tumorigenicity. Oncogene (2003) 1.76
Notch signaling inhibits hepatocellular carcinoma following inactivation of the RB pathway. J Exp Med (2011) 1.74
Gastric cancer-molecular and clinical dimensions. Nat Rev Clin Oncol (2013) 1.72
Genome-scale profiling of gene expression in hepatocellular carcinoma: classification, survival prediction, and identification of therapeutic targets. Gastroenterology (2004) 1.71
Integrative genomic identification of genes on 8p associated with hepatocellular carcinoma progression and patient survival. Gastroenterology (2011) 1.68
Restoration of DLC-1 gene expression induces apoptosis and inhibits both cell growth and tumorigenicity in human hepatocellular carcinoma cells. Oncogene (2004) 1.65
Integrative analysis of proteomic signatures, mutations, and drug responsiveness in the NCI 60 cancer cell line set. Mol Cancer Ther (2010) 1.62
Transcriptome analysis of liver cancer: ready for the clinic? J Hepatol (2009) 1.60
Periostin, a cell adhesion molecule, facilitates invasion in the tumor microenvironment and annotates a novel tumor-invasive signature in esophageal cancer. Cancer Res (2010) 1.58
Transcriptomic profiling reveals hepatic stem-like gene signatures and interplay of miR-200c and epithelial-mesenchymal transition in intrahepatic cholangiocarcinoma. Hepatology (2012) 1.57
Cyclin G recruits PP2A to dephosphorylate Mdm2. Mol Cell (2002) 1.57
Expression profile of the tumor suppressor genes DLC-1 and DLC-2 in solid tumors. Int J Oncol (2006) 1.53
Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor-resistant human lung adenocarcinoma. J Clin Invest (2011) 1.52
Transient activation of NF-kappaB through a TAK1/IKK kinase pathway by TGF-beta1 inhibits AP-1/SMAD signaling and apoptosis: implications in liver tumor formation. Oncogene (2003) 1.52
Nonclassic functions of human topoisomerase I: genome-wide and pharmacologic analyses. Cancer Res (2007) 1.51
Functional and genomic implications of global gene expression profiles in cell lines from human hepatocellular cancer. Hepatology (2002) 1.51
Central role of c-Myc during malignant conversion in human hepatocarcinogenesis. Cancer Res (2009) 1.50
DLC-1, a Rho GTPase-activating protein with tumor suppressor function, is essential for embryonic development. FEBS Lett (2005) 1.45
Identification of potential driver genes in human liver carcinoma by genomewide screening. Cancer Res (2009) 1.45
Loss of hepatocyte growth factor/c-Met signaling pathway accelerates early stages of N-nitrosodiethylamine induced hepatocarcinogenesis. Cancer Res (2007) 1.43
Hepatocyte-stellate cell cross-talk in the liver engenders a permissive inflammatory microenvironment that drives progression in hepatocellular carcinoma. Cancer Res (2012) 1.43
Integrative analysis of cyclin protein levels identifies cyclin b1 as a classifier and predictor of outcomes in breast cancer. Clin Cancer Res (2009) 1.43
Aberrant methylation and deacetylation of deleted in liver cancer-1 gene in prostate cancer: potential clinical applications. Clin Cancer Res (2006) 1.43
Targeted delivery of small interfering RNA using reconstituted high-density lipoprotein nanoparticles. Neoplasia (2011) 1.42
Promoter hypermethylation of DLC-1, a candidate tumor suppressor gene, in several common human cancers. Cancer Genet Cytogenet (2003) 1.42
Comprehensive genomic meta-analysis identifies intra-tumoural stroma as a predictor of survival in patients with gastric cancer. Gut (2012) 1.42
Cross-species hybridization of microarrays for studying tumor transcriptome of brain metastasis. Proc Natl Acad Sci U S A (2011) 1.41
Gene expression-based recurrence prediction of hepatitis B virus-related human hepatocellular carcinoma. Clin Cancer Res (2008) 1.41
Chemotherapy and radiotherapy resistance: complexity, reality, and promise. J Clin Oncol (2008) 1.39
RB loss abrogates cell cycle control and genome integrity to promote liver tumorigenesis. Gastroenterology (2007) 1.36
Wild-type p53 controls cell motility and invasion by dual regulation of MET expression. Proc Natl Acad Sci U S A (2011) 1.36
Disruption of beta-catenin pathway or genomic instability define two distinct categories of liver cancer in transgenic mice. Gastroenterology (2004) 1.35
Oncogene-specific gene expression signatures at preneoplastic stage in mice define distinct mechanisms of hepatocarcinogenesis. Hepatology (2006) 1.34
Hepatocyte growth factor/c-met signaling is required for stem-cell-mediated liver regeneration in mice. Hepatology (2012) 1.33
Intact signaling by transforming growth factor beta is not required for termination of liver regeneration in mice. Hepatology (2004) 1.33
Prognostic biomarkers for esophageal adenocarcinoma identified by analysis of tumor transcriptome. PLoS One (2010) 1.33
Prognostic gene expression signature associated with two molecularly distinct subtypes of colorectal cancer. Gut (2011) 1.32
Met and the epidermal growth factor receptor act cooperatively to regulate final nephron number and maintain collecting duct morphology. Development (2009) 1.31